Cwm LLC Acquires 2,641 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Cwm LLC increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 10,157.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,667 shares of the company’s stock after acquiring an additional 2,641 shares during the period. Cwm LLC’s holdings in Keros Therapeutics were worth $27,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. FNY Investment Advisers LLC bought a new position in Keros Therapeutics in the first quarter worth approximately $25,000. Rhumbline Advisers grew its holdings in Keros Therapeutics by 9.3% in the first quarter. Rhumbline Advisers now owns 44,669 shares of the company’s stock worth $455,000 after purchasing an additional 3,802 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Keros Therapeutics by 7,690.3% during the first quarter. GAMMA Investing LLC now owns 2,415 shares of the company’s stock valued at $237,000 after buying an additional 2,384 shares during the last quarter. TFG Asset Management GP Ltd purchased a new stake in shares of Keros Therapeutics during the fourth quarter valued at $1,630,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Keros Therapeutics by 27.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 64,416 shares of the company’s stock valued at $1,020,000 after buying an additional 13,864 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $14.39 on Wednesday. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market capitalization of $584.52 million, a P/E ratio of -79.94, a PEG ratio of 2.64 and a beta of 1.33. The company has a 50 day moving average price of $14.06 and a 200 day moving average price of $12.74.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. The business had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. During the same period last year, the business earned ($1.21) EPS. Research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of recent research reports. Bank of America lowered Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $32.00 to $18.00 in a research note on Tuesday, June 10th. Scotiabank decreased their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating for the company in a research report on Monday, May 12th. Wedbush reiterated a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research report on Friday, May 30th. HC Wainwright reduced their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Finally, Truist Financial cut their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $30.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.